SCHEMBL6804436

SCHEMBL6804436

CCNC(=N)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
HTT P42858 2/20 0.49
MEN1 O00255 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TSHR P16473 1/20 0.49
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
HTR6 P50406 1/20 0.45
TDP1 Q9NUW8 1/20 0.43
FBP1 P09467 1/20 0.42
PSEN1 P49768 2/20 0.42
PSEN2 P49810 2/20 0.42
APH1B Q8WW43 2/20 0.42
NCSTN Q92542 2/20 0.42
APH1A Q96BI3 2/20 0.42
PSENEN Q9NZ42 2/20 0.42
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
CCR4 P51679 2/20 0.41
P2RY12 Q9H244 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6802725 0.84 KMT2A (0.66) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL265540 0.84 FBP1 (0.52) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL6801528 0.76 ALDH1A1 (0.43) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL16012975 0.76 KMT2A (0.67) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL7566282 0.75 CDK1 (0.46) ALDH1A1TDP1
SCHEMBL682128 0.74 MAPT (0.63) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL195598 0.73 P2RY12 (0.53) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL194745 0.73 MAPT (0.53) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL6804437 0.72 HTR6 (0.55) KMT2AHTTMEN1SMN1; SMN2TSHR
SCHEMBL8869532 0.72 P4HTM (0.45) KMT2AFBP1CCR4P2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040010142-A1 Novel process NOVO NORDISK A/S (DK) 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010142-A1 Novel process UGT1A1, CYP4X1, CYP4B1 KMT2A 4646/4885HTT 4010/4885MEN1 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.